In the tested NSCLC cells, ADCK2 shRNA reduced CCK-8 viability (Figure 3J), decreased EdU-stained nuclei ratio , (Figure 3K) and slowed in vitro cell migration (Figure 3L). This evidence concerns the gene ADCK2 and non-small cell lung carcinoma.